UN Sanctions and Drug Supplies In Iraq

23 January 1995

Although the United Nations sanctions imposed on Iraq in August 1990 were not intended to affect food and drug supplies, the sales embargo placed on Iraqi oil means the country does not have the foreign exchange to buy food and drugs, writes Susan Funnell in The Pharmaceutical Journal this month.

Describing visits she made to Iraq with the UK charity Medical Aid for Iraq last year, Ms Funnell says the medical supplies which Iraqi hospitals receive each month from the Ministry of Health provide only about 5% of real requirements. All drugs are in extremely short supply; some hospitals visited by MAI did not even have analgesics. Intravenous drugs are particularly lacking and frequently unavailable, while antibiotics are given in half doses and frequently changed daily, depending on what is available, and children being treated at the cancer center in Medical City, Baghdad, receive chemotherapy at half the recommended dose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight